Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 24;14:6761. doi: 10.1038/s41467-023-42400-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Oncoplot showing potentially clinically relevant tumor gene alterations (SNVs/indels, gene deletions and amplifications) as assessed by comprehensive genomic profiling of baseline biopsy samples. Curated pathways and selected genes altered in 10% or more patients are shown. A column represents a patient and is grouped by the best response (indicated by vertical dashed lines) and related clinicopathologic features (n = 29); gray shaped columns indicate patients where an unambiguous CNA profile statement was impossible. Top bar chart represents tumor mutational burden (TMB). Percentages listed right represent the proportion of patients harboring an alteration in the gene listed left. Bottom bars show radiological response assessment, heatmaps of PFS and OS (both in months, censored patients marked with dots), CUP histology, ECOG status, number of therapy lines prior to ICI treatment, number of organs with metastases, heatmap of metastasis burden score (MBS), and PD-L1 expression status. b Kaplan-Meier estimates of PFS and OS, stratified according to activating RAS alterations: activated (n = 9) and wild-type (n = 20). c Kaplan-Meier estimates of PFS and OS, stratified according to functionally deleterious TP53 alterations: deleterious (n = 11) and wild-type (n = 18). d Kaplan-Meier estimates of PFS and OS, stratified according to low (n = 11) or high (n = 8) aneuploidy score (AS) of baseline FFPE tumor tissue, based on the median cohort AS value of 9. In (b-d), comparisons are made using a two-sided log-rank test, Cox proportional hazard regression modeling was used to calculate hazard ratio. 95% CI 95% confidence interval, HR hazard ratio, CR complete response, PR partial response, SD stable disease, PD progressive disease, FFPE formalin-fixed paraffin-embedded, AS aneuploidy score, NE not evaluable, ND not determined. Source data are provided as a Source Data file.